Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 2/20 | 0.58 |
| ▸ | PDE8A | O60658 | 10/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16134183 | 0.84 | CCNE1 (0.69) | PI4KAPI4K2BPI4K2API4KBCDK1 | |
| SCHEMBL179425 | 0.83 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBCDK1 | |
| SCHEMBL3440998 | 0.83 | CDK1 (0.71) | PI4KAPI4K2BPI4K2API4KBCDK1 | |
| SCHEMBL23619320 | 0.81 | CDK1 (0.60) | CDK1PDE8ACCNB1CCNE1CDK2 | |
| SCHEMBL3441081 | 0.80 | CDK1 (0.64) | CDK1PDE8ACCNB1CCNE1CDK2 | |
| SCHEMBL6884460 | 0.79 | HSP90AB1 (0.55) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24026363 | 0.79 | CDK1 (0.58) | CDK1PDE8ACCNB1CCNE1CDK2 | |
| SCHEMBL3441119 | 0.79 | CDK1 (0.58) | CDK1PDE8ACCNB1CCNE1CDK2 | |
| SCHEMBL179439 | 0.78 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBCDK1 | |
| SCHEMBL14024978 | 0.78 | ADORA2A (0.62) | CDK1PDE8ACCNB1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | PI4KA 3541/4885PI4K2B 4005/4885PI4K2A 3818/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | PI4KA 3541/4885PI4K2B 4005/4885PI4K2A 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.